icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
61th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2010
Back grey_arrow_rt.gif
 
 
 
A Phase IIa, open-label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6
 
 
  Reported by Jules Levin
AASLD Nov 2 2010 Boston
 
C. Moreno,1 T. Berg,2 T. Tanwandee,3 S. Thongsawat,4 H. Van Vlierberghe,5 S. Zeuzem,6 O. Lenz,7 M. Peeters,7 V. Sekar,8 G. De Smedt7 1Department of Gastroenterology and Hepatopancreatology, H˘pital Erasme, UniversitÚ Libre de Bruxelles, Bruxelles, Belgium; 2Department of Hepatology, Clinic of Gastroenterology and Rheumatology, University Clinic Leipzig, Leipzig, Germany; 3Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; 4Chiang Mai University, Chiang Mai, Thailand; 5Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium; 6Department of Medicine I, J.W. Goethe University Hospital, Frankfurt, Germany; 7Tibotec, Beerse, Belgium; 8Tibotec Inc., Titusville, NJ, USA Disclosure: C. Moreno is an investigator for Roche, Gilead, Schering Plough, Pfizer, and Tibotec, is a speaker for Schering Plough and BMS, and is a consultant/advisor for Janssen-Clegg and Schering Plough; T. Berg is a consultant and member of a speaker bureau for Roche, Schering Plough, Vertex, Janssen-Cilag, Tibotec, Novartis, BMS, and Gilead; T. Tanwandee has received research grant support from Roche, MSD, Novartis, Human Genome Science, Celsion, and Tibotec; S. Thongsawat and H. Van Vlierberghe have no disclosures to declare; S. Zeuzum is a consultant for Abbott, Achillion, Anadys, BMS, Gilead, GSK, HGS, Merck, Novartis, Pharmasset, Roche, Santaris, Vertex, and Tibotec; O. Lenz, M. Peeters, V. Sekar, and G. De Smedt are all employees of Tibotec.